The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Integrated CDMO and CRO services to accelerate time to market
This infographic explains how integrating CDMO and CRO services under a single partner can help reduce complexity and support faster, more connected drug development execution.
Integrating contract development and manufacturing organization (CDMO) and contract research organization (CRO) services can help sponsors reduce the complexity that often comes with managing multiple vendors across drug development. A more connected approach may support clearer timelines, fewer handoffs, and improved coordination from early development through commercialization.
A CDMO provides development and manufacturing services, while a CRO supports clinical research and trial execution. When these capabilities are integrated, sponsors may be able to streamline execution across stages while maintaining quality and regulatory focus.
What you’ll learn in this infographic
Key themes in the infographic include:
- How integrated timelines and centralized coordination can support faster decision-making
- How fewer vendor handoffs may help reduce operational complexity
- How milestone visibility can support proactive risk identification and mitigation
- How integrated teams can support speed, simplicity, and scalability across programs
- How global networks with regional expertise can support scale-up through clinical trials and commercialization
Explore Accelerator™ Drug Development, an integrated approach combining CDMO and CRO capabilities across clinical research, manufacturing, and clinical supply.
Why integration may matter for some programs
For programs where fragmented vendor models introduce avoidable handoffs or coordination challenges, an integrated CDMO and CRO approach may help support continuity across clinical research, manufacturing, and supply—depending on program needs and complexity.
